According to the product information for paracetamol in the European Union, extensive data collected from pregnant women who have taken paracetamol during their pregnancies shows no evidence of malformations in either the developing fetus or newborns. In 2019, the European Medicines Agency (EMA) conducted a review of existing research concerning the neurodevelopment of children exposed to paracetamol while in utero. The findings were inconclusive, and no definitive connection to neurodevelopmental disorders was identified. For further details, please refer to footnotes 1 and 2.
Paracetamol is deemed safe for use during pregnancy when necessary. Like any medication used for short-term treatment, it is advised to be taken at the lowest effective dosage, for the shortest duration, and as infrequently as possible. Pregnant women are encouraged to consult their healthcare providers with any inquiries regarding medication use during pregnancy.
The EMA, along with national authorities within the EU, will continue to oversee the safety of paracetamol-containing medications and will assess any new information as it becomes available. Regulatory measures will be implemented as needed to safeguard public health.
Source link
